Sterling Biotech rose 0.55% to Rs 9.10 at 10:20 IST on BSE after the company said it has completed the cashless exchange offer by issue of zero coupon convertible bonds due 2019 aggregating $206.464 million in exchange of existing bonds.
The announcement was made after market hours on Monday, 24 March 2014.
Meanwhile, the S&P BSE Sensex was down 47.78 points or 0.22% at 22,007.70.
On BSE, so far 51,000 shares were traded in the counter as against average daily volume of 94,806 shares in the past one quarter.
The stock was volatile. The stock surged as much as 3.86% at the day's high of Rs 9.40 so far during the day. The stock rose 0.55% at the day's low of Rs 9.10 so far during the day. The stock had hit a 52-week high of Rs 10.45 on 25 November 2013. The stock had hit a 52-week low of Rs 4.01 on 25 March 2013.
The stock had outperformed the market over the past one month till 24 March 2014, surging 34.07% compared with the Sensex's 5.98% rise. The scrip had also outperformed the market in past one quarter, jumping 12.84% as against Sensex's 4.86% rise.
More From This Section
The small-cap company has equity capital of Rs 26.79 crore. Face value per share is Re 1.
As per the terms of the cashless exchange offer, now the company's obligations to the holders of the existing bonds with respect to payment of principal, interest, default interest, and premium on existing bonds stands discharged in full and no other amounts shall be payable to the holders of existing bonds, Sterling Biotech said in a statement.
Sterling Biotech said that the fresh FCCBs carry a zero coupon with a yield to maturity of 5.43% per annum (calculated on semi-annual basis). The FCCBs will mature on 25 March 2019. These are convertible into ordinary shares or GDRs of the company. These FCCBs are convertible at any time after 5 May 2014 at a conversion price of Rs 60 per share with fixed rate of exchange on conversion of Rs 48 per dollar, the company said. The FCCBs will be admitted to trading on the Euro MTF market of Luxembourg Stock Exchange, Sterling Biotech said in a statement.
Sterling Biotech reported a net loss of Rs 105.99 crore in Q4 December 2013, higher than net loss of Rs 91.06 crore in Q4 December 2012. Net sales declined 25.9% to Rs 150.75 crore in Q4 December 2013 over Q4 December 2012.
Sterling Biotech's core business is the manufacture of gelatin for pharmaceutical and edible uses.
Powered by Capital Market - Live News